Author:
Miura Masatomo,Takahashi Naoto,Sawada Ken-ichi
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry
Reference8 articles.
1. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma;De Francia;Journal of Chromatography B: Biomedical Sciences and Applications,2009
2. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia;Deremer;Clinical Therapeutics,2008
3. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry;Haouala;Journal of Chromatography B: Biomedical Sciences and Applications,2009
4. Gathmann I and Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study;Larson;Blood,2008
5. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia;Picard;Blood,2007
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献